DRG Epidemiology’s coverage of endometrial cancer comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of endometrial cancer for each country, as well as annualized case counts projected to the national population.
Most patient populations in the major mature pharmaceutical markets are forecast over a period of 20 years and patient populations in other countries over a period of 10 years. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.
DRG Epidemiology’s endometrial cancer forecast will answer the following questions:
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
Note: Coverage may vary by country.